OSI-774 and Bevacizumab in the Treatment of Patients With Metastatic Renal Cell Carcinoma
In this phase II trial, we plan to evaluate the combination of Tarceva and Avastin in the treatment of patients with metastatic renal cell carcinoma. This trial will be one of the first phase II trials to evaluate a combination of targeted agents in the treatment of a common solid tumor with a strong biologic rationale based on Cancer Biology (VHL/HIF/VEGF/EGFr).
Kidney Cancer
DRUG: OSI-774|DRUG: Bevacizumab
Efficacy of the combination of Tarceva and Avastin, 18 months
Objective response rate, 18 months|Progression-free survival, 18 months|Overall Survival, 18 months|Overall tolerability and toxicity of this combination regimen, 18 months
Upon determination of eligibility, all patients will receive:

Tarceva + Avastin